Targeted therapies ensure more durable responses, better overall responses, and lower toxicity than historical therapy for patients whose tumors harbor oncogenic drivers, such as EGFR, ALK, ROS1,
though questions remain on their placement beyond progression.
, and stressed the significance of molecular testing.
OncLive: What are some of the updates with oncogene-driven NSCLC that you shared?
For my presentation, I spoke about the established genetic alterations for which we have approved targeted therapies. Those include EGFR
activating mutations, ALK
fusions, and BRAF V600E mutations. We saw data from the FLAURA study presented within the past year suggesting that first-line osimertinib provides a PFS benefit for patients with traditional EGFR
activating mutations; those include exon 19 deletions and L858R point mutations in exon 21. The PFS benefit for osimertinib compared with gefitinib or erlotinib was [nearly] 19 months versus 10 months.
... to read the full story